Bioclinica, Inc. (BIOC) Tops Q4 EPS by 2c, Sales Beat Expectations

Bioclinica, Inc. (NASDAQ: BIOC) reported Q4 EPS of $0.09, $0.02 better than the analyst estimate of $0.07. Revenue for the quarter came in at $22.57 million versus the consensus estimate of $20.84 million.

For earnings history and earnings-related data on Bioclinica, Inc. (BIOC) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
• Mount Logan Capital Inc. (MLCI) Reports Q2 Loss of $0.37
• Integra Resources (ITRG) Tops Q2 EPS by 6c